caa a22 4500 605491607 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0810-y doi (NATIONALLICENCE)springer-10.1007/s10147-015-0810-y Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial [Elektronische Daten] [Yasuo Hirayama, Kunihiko Ishitani, Yasushi Sato, Satoshi Iyama, Kohichi Takada, Kazuyuki Murase, Hiroyuki Kuroda, Yasuhiro Nagamachi, Yuichi Konuma, Akihito Fujimi, Tamotsu Sagawa, Kaoru Ono, Hiroto Horiguchi, Takeshi Terui, Kazuhiko Koike, Toshiro Kusakabe, Tsutomu Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato] Background: Chemotherapy-induced peripheral neuropathy (CIPN) is difficult to manage. A phase III trial conducted in the United States demonstrated that duloxetine was effective for CIPN caused by taxane and platinum-based chemotherapy. No randomized trial of duloxetine for CIPN has been conducted in Japan. Methods: In this open-label, randomized, crossover study, eligible patients were randomized to Group A or Group B. Group A received duloxetine 20mg/day orally for the first week and 40mg/day for the next 3weeks. Group B received vitamin B12 (VB12) 1.5mg/day orally for 4weeks. After a 2- to 4-week washout period, treatment was crossed over for another 4weeks. The severity of numbness and pain was assessed using a visual analog scale (VAS). Results: Thirty-four patients were enrolled. Obvious decreases in the mean VAS scores for numbness and pain were observed for the periods of duloxetine administration. Significant differences were observed between the duloxetine-first (Group A) and the VB12-first (Group B) groups with respect to numbness (p=0.03) and pain (p=0.04) at 4weeks after administration. Fatigue was observed in six of the 34 participants (17.6%). Conclusions: Our data suggests that duloxetine has a beneficial effect on CIPN caused by oxaliplatin, paclitaxel, vincristine, or bortezomib in Japanese patients. Japan Society of Clinical Oncology, 2015 Duloxetine nationallicence Neuropathy nationallicence Chemotherapy nationallicence Supportive care nationallicence CIPN nationallicence Hirayama Yasuo Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut Ishitani Kunihiko Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan aut Sato Yasushi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Iyama Satoshi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Takada Kohichi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Murase Kazuyuki Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Kuroda Hiroyuki Department of Hematology Oncology, Seitetsu Memorial Hospital, Muroran, Japan aut Nagamachi Yasuhiro Department of Hematology Oncology, Kiyota Hospital, Sapporo, Japan aut Konuma Yuichi Department of Hematology Oncology, Asahikawa Red Cross Hospital, Asahikawa, Japan aut Fujimi Akihito Department of Hematology Oncology, Oji Genaral Hospital, Tomakomai, Japan aut Sagawa Tamotsu Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan aut Ono Kaoru Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Horiguchi Hiroto Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Terui Takeshi Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut Koike Kazuhiko Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan aut Kusakabe Toshiro Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut Sato Tsutomu Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Takimoto Rishu Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Kobune Masayoshi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut Kato Junji Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 866-871 1341-9625 20:5<866 2015 20 10147 https://doi.org/10.1007/s10147-015-0810-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0810-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hirayama Yasuo Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut NATIONALLICENCE 700 1- Ishitani Kunihiko Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan aut NATIONALLICENCE 700 1- Sato Yasushi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Iyama Satoshi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Takada Kohichi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Murase Kazuyuki Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Kuroda Hiroyuki Department of Hematology Oncology, Seitetsu Memorial Hospital, Muroran, Japan aut NATIONALLICENCE 700 1- Nagamachi Yasuhiro Department of Hematology Oncology, Kiyota Hospital, Sapporo, Japan aut NATIONALLICENCE 700 1- Konuma Yuichi Department of Hematology Oncology, Asahikawa Red Cross Hospital, Asahikawa, Japan aut NATIONALLICENCE 700 1- Fujimi Akihito Department of Hematology Oncology, Oji Genaral Hospital, Tomakomai, Japan aut NATIONALLICENCE 700 1- Sagawa Tamotsu Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan aut NATIONALLICENCE 700 1- Ono Kaoru Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Horiguchi Hiroto Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Terui Takeshi Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut NATIONALLICENCE 700 1- Koike Kazuhiko Division of Palliative Care, Higashi Sapporo Hospital, Sapporo, Japan aut NATIONALLICENCE 700 1- Kusakabe Toshiro Department of Hematology Oncology, Higashi Sapporo Hospital, Higashi Sapporo, Shiroishi-ku, 003-8585, Sapporo, Japan aut NATIONALLICENCE 700 1- Sato Tsutomu Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Takimoto Rishu Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Kobune Masayoshi Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Kato Junji Department of Medical Oncology/Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 866-871 1341-9625 20:5<866 2015 20 10147